Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This study found that among users of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide were associated with higher incidences of hair loss, particularly androgenetic alopecia and telogen effluvium, with rapid weight loss identified as a potential contributor to telogen effluvium.

This narrative review identifies telogen effluvium as a growing concern linked to weight-loss interventions, such as GLP-1 receptor agonists and bariatric surgery, attributing hair loss to systemic and metabolic stress rather than permanent hair follicle damage.

This review article discusses the aesthetic impacts of GLP-1 medications like Ozempic (semaglutide), including "Ozempic Face," skin sagging, and loss of lean mass, and explores potential recovery methods such as biostimulators, HIFU, endolaser, and PRP.

This review observed that semaglutide may have therapeutic benefits for skin conditions like psoriasis and hidradenitis suppurativa, but reports of adverse skin reactions exist, indicating the need for further research to understand its safety and efficacy in dermatology.

This case study highlights an adolescent girl with atypical anorexia nervosa who experienced mental health changes after using semaglutide, underscoring the need for cautious prescription and follow-up of this medication to prevent adverse effects in vulnerable individuals.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

Tailored medication preparation and ongoing education are crucial for effective treatments.

This report details a six-month pharmacy internship in Portugal, where the author engaged in hospital and community pharmacy settings, and discusses scientific topics including obesity medication risks and alopecia treatment options. Results and conclusions are not explicitly reported.

In this observational study, researchers found that new users of tirzepatide experienced a higher incidence of alopecia compared to semaglutide users over a 12-month period, with increased risk persisting even when accounting for achieved weight loss and treatment duration.

This source provides an overview of diagnostic and treatment innovations for gastrointestinal disorders, such as wireless capsule technology for motility assessment and new methods for treating constipation and nausea, highlighting both current and emerging techniques.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.

This study found that men experiencing persistent sexual side effects from finasteride also commonly report depressive symptoms and suicidal thoughts.

This study found that semaglutide significantly reduced body weight in almost 80% of obese PCOS patients unresponsive to lifestyle changes, often normalizing menstrual cycles with few side effects.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

This study observed that dermatological and hair changes, like skin sagging and hair shedding, commonly occur early during weight loss with GLP-1 receptor agonists, highlighting the need for tailored dermatological care alongside treatment.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

This study introduces Cell Journey, a new platform for visualizing RNA velocity in 3D, which aims to better capture complex cellular transitions in single-cell datasets compared to current 2D methods.

This article discusses Fluxactive Complete, a natural supplement for prostate health, and reports no new clinical results.

This abstract outlines a lecture discussing the rise of influencers alongside the internet, highlighting their impact on user behavior in social media by sharing personal experiences and engaging in political and medical discourse.

In this study, researchers developed an in-situ gel formulation of antibacterial Levofloxacin for the eye, which showed prolonged drug release, increased residence time, and effective antibacterial action, suggesting it may be a safe and effective ocular delivery system for antibiotics.

This study discusses promising research advancements that may improve treatment outcomes for glioblastomas, highlighting stereotactic radiosurgery, FET-PET imaging, and alternating electric field therapy as potential strategies. The abstract emphasizes the need for ongoing and future trials to determine their effectiveness in clinical practice.

This study highlights the benefits of virtual surgical planning in orthognathic and facial trauma surgeries, noting its ability to enhance understanding of complex 3D anatomical relationships, reduce operation time, and integrate multidisciplinary approaches, including robotic assistance for real-time adjustments and customized implants.

This review discusses various applications of foam systems in drug form technology, highlighting their potential to enhance drug solubility and release modifications, but reports no new clinical results.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This study found that bio-based waterborne polyurethanes derived from castor oil may offer effective hair-styling performance without skin irritation and appear to be safer for the environment compared to traditional hair sprays.